Clinical Trials · NCT05971940
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 559
- Start date
- Aug 2023
- Locations
- 89 sites, 6 countries
- Primary endpoint
- Change From Baseline in HbA1c